Nemolizumab
Monoclonal antibody
- D11AH12 (WHO)
- 1476039-58-3
- none
- GN465U8B72
- D11080
Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis.[1] It is a monoclonal antibody that blocks the interleukin-31 receptor A.[2] Results of a Phase II clinical trial were published in March 2017.[3]
Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016.[4]
References
- ^ Spreitzer H (27 March 2017). "Neue Wirkstoffe - Nemolizumab". Österreichische Apothekerzeitung (in German) (7/2017).
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 74" (PDF). WHO Drug Information. 29 (3). World Health Organization: 411. 2015.
- ^ Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. (March 2017). "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis". The New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150. S2CID 205100502.
- ^ "Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma". Pharmabiz.com. 22 July 2016.
- v
- t
- e
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e